Hikma Pharmaceuticals (LON:HIK) Share Price Crosses Above 200 Day Moving Average – Should You Sell?

Posted by ABMN Staff on Jul 15th, 2026

Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report)’s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,448.89 and traded as high as GBX 1,569. Hikma Pharmaceuticals shares last traded at GBX 1,509.61, with a volume of 42,938,281 shares traded.

Analysts Set New Price Targets

Several analysts recently issued reports on HIK shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 195 price target on shares of Hikma Pharmaceuticals in a research report on Monday, June 22nd. Jefferies Financial Group boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Finally, Berenberg Bank restated a “buy” rating and set a GBX 1,800 target price on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Hikma Pharmaceuticals presently has an average rating of “Buy” and an average price target of GBX 1,687.

Read Our Latest Analysis on Hikma Pharmaceuticals

Hikma Pharmaceuticals Stock Down 4.1%

The company has a quick ratio of 1.27, a current ratio of 1.82 and a debt-to-equity ratio of 61.84. The firm has a 50 day moving average of GBX 1,486.36 and a two-hundred day moving average of GBX 1,448.89. The firm has a market capitalization of £3.18 billion, a price-to-earnings ratio of 8.34, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65.

About Hikma Pharmaceuticals

(Get Free Report)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.